Some people are facing delays in filling prescriptions for the glucose sensor. Abbott expects to resolve the problem soon.

The FDA designated Abbott's recall of FreeStyle Libre 3 sensors as the most serious, class I type due to the risk for ...

Abbott (NYSE:ABT) faces a proposed class action lawsuit related to alleged tracking tools used with its FreeStyle Libre ...

Some better-ranked stocks in the broader medical space are TransMedix Group TMDX, Veracyte VCYT and Boston Scientific BSX. While TransMedix Group and Veracyte currently sport a Zacks Rank #1 (Strong ...

Foreign exchange fluctuation is a major headwind for ABT, as a considerable percentage of its revenues comes from outside the ...

Abbott's strong innovation pipeline, including advancements in CGM systems, supports its market share gains and growth ...

Abbott Diabetes Care, Inc. is recalling its FreeStyle Libre 3 sensors after finding a small number of the sensors may provide incorrect high glucose readings, which, if undetected may pose ...

ABT made its CGM system Lingo available in the United States. The system can be used by consumers aged 18 years and older who ...

The t:slim X2 pump is currently cleared for use with Humalog and Novolog/NovoRapid U-100 insulins globally, and Admelog/Insulin lispro Sanofi and Trurapi/Insulin aspart Sanofi U-100 insulins in Canada ...

RHHBY's Accu-Chek Smartguide will provide several predictive features aimed at enhancing patient safety. However, the device ...